Literature DB >> 12797503

Indirect airway challenges.

G F Joos1, B O'Connor, S D Anderson, F Chung, D W Cockcroft, B Dahlén, G DiMaria, A Foresi, F E Hargreave, S T Holgate, M Inman, J Lötvall, H Magnussen, R Polosa, D S Postma, J Riedler.   

Abstract

Indirect challenges act by causing the release of endogenous mediators that cause the airway smooth muscle to contract. This is in contrast to the direct challenges where agonists such as methacholine or histamine cause airflow limitation predominantly via a direct effect on airway smooth muscle. Direct airway challenges have been used widely and are well standardised. They are highly sensitive, but not specific to asthma and can be used to exclude current asthma in a clinic population. Indirect bronchial stimuli, in particular exercise, hyperventilation, hypertonic aerosols, as well as adenosine, may reflect more directly the ongoing airway inflammation and are therefore more specific to identify active asthma. They are increasingly used to evaluate the prevalence of bronchial hyperresponsiveness and to assess specific problems in patients with known asthma, e.g. exercise-induced bronchoconstriction, evaluation before scuba diving. Direct bronchial responsiveness is only slowly and to a modest extent, influenced by repeated administration of inhaled steroids. Indirect challenges may reflect more closely acute changes in airway inflammation and a change in responsiveness to an indirect stimulus may be a clinically relevant marker to assess the clinical course of asthma. Moreover, some of the indirect challenges, e.g. hypertonic saline and mannitol, can be combined with the assessment of inflammatory cells by induction of sputum.

Entities:  

Mesh:

Year:  2003        PMID: 12797503     DOI: 10.1183/09031936.03.00008403

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  58 in total

1.  Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma.

Authors:  M Delvaux; M Henket; L Lau; P Kange; P Bartsch; R Djukanovic; R Louis
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

2.  Airway immunopathology of asthma with exercise-induced bronchoconstriction.

Authors:  Teal S Hallstrand; Mark W Moody; Moira L Aitken; William R Henderson
Journal:  J Allergy Clin Immunol       Date:  2005-09       Impact factor: 10.793

3.  Screening elite winter athletes for exercise induced asthma: a comparison of three challenge methods.

Authors:  J W Dickinson; G P Whyte; A K McConnell; M G Harries
Journal:  Br J Sports Med       Date:  2006-02       Impact factor: 13.800

4.  Safety of sputum induction with hypertonic saline solution in exercise-induced bronchoconstriction.

Authors:  Chris Carlsten; Moira L Aitken; Teal S Hallstrand
Journal:  Chest       Date:  2007-05       Impact factor: 9.410

Review 5.  Effects of exercise training on airway hyperreactivity in asthma: a systematic review and meta-analysis.

Authors:  Philipp A Eichenberger; Stephanie N Diener; Reto Kofmehl; Christina M Spengler
Journal:  Sports Med       Date:  2013-11       Impact factor: 11.136

Review 6.  [Lung function].

Authors:  S Sorichter
Journal:  Radiologe       Date:  2009-08       Impact factor: 0.635

Review 7.  Diagnostic exercise challenge testing.

Authors:  Christopher Randolph
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

Review 8.  Epithelial regulation of eicosanoid production in asthma.

Authors:  Teal S Hallstrand; Ying Lai; William R Henderson; William A Altemeier; Michael H Gelb
Journal:  Pulm Pharmacol Ther       Date:  2012-12       Impact factor: 3.410

9.  Finding better therapeutic targets for patients with asthma: adenosine receptors?

Authors:  R Polosa
Journal:  Br J Pharmacol       Date:  2008-10       Impact factor: 8.739

10.  Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes.

Authors:  Teal S Hallstrand; Mark M Wurfel; Ying Lai; Zhanglin Ni; Michael H Gelb; William A Altemeier; Richard P Beyer; Moira L Aitken; William R Henderson
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.